Medication info
Tradjult MPA Sustained Release Tablet 10/5/1000 mg (Empagliflozin, Linagliptin, Metformin)

Tradjult MPA Sustained Release Tablet 10/5/1000 mg (Empagliflozin, Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tabletLinagliptin›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Yuhan Corporation
Appearance
Yellow oval film-coated sustained release tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501955 · Approved 2025.07.29 · Insurance code 642106350

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Determine the dose of this drug based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily dose of each component: empagliflozin 25mg, linagliptin 5mg, and metformin hydrochloride extended-release 2000mg. Take this drug once daily in the evening with a meal. If the metformin hydrochloride dose needs adjustment, adjust it gradually. Patients taking this drug as extended-release tablets containing 10/5/1000 mg or 25/5/1000 mg should take 1 tablet once daily. The recommended starting dose is empagliflozin 10 mg/linagliptin 5 mg/metformin hydrochloride 1000mg once daily; if additional glycemic control is needed, the dose may be increased to 25/5/1000 mg once daily. To maintain the extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. Dose adjustment is required in patients with renal impairment according to renal function; the metformin hydrochloride dose may be adjusted in patients with moderate renal impairment. The starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If the estimated glomerular filtration rate is below 45 mL/min/1.73m2, discontinue this drug immediately.

Ingredients

Manufacturer
Yuhan Corporation

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is prescribed to assist in blood sugar control for patients with type 2 diabetes when used alongside empagliflozin, linagliptin, and metformin. It helps to effectively manage blood sugar through a combination of dietary management and physical activity, thereby improving blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

Determine the dose of this drug based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily dose of each component: empagliflozin 25mg, linagliptin 5mg, and metformin hydrochloride extended-release 2000mg. Take this drug once daily in the evening with a meal. If the metformin hydrochloride dose needs adjustment, adjust it gradually. Patients taking this drug as extended-release tablets containing 10/5/1000 mg or 25/5/1000 mg should take 1 tablet once daily. The recommended starting dose is empagliflozin 10 mg/linagliptin 5 mg/metformin hydrochloride 1000mg once daily; if additional glycemic control is needed, the dose may be increased to 25/5/1000 mg once daily. To maintain the extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. Dose adjustment is required in patients with renal impairment according to renal function; the metformin hydrochloride dose may be adjusted in patients with moderate renal impairment. The starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If the estimated glomerular filtration rate is below 45 mL/min/1.73m2, discontinue this drug immediately.

Precautions

This medication may cause a rare complication known as lactic acidosis, which can lead to death in severe cases, so caution is required. This medication should not be used by individuals who are allergic to the active or inactive ingredients, patients with type 1 diabetes, patients with acute or chronic metabolic acidosis, patients undergoing dialysis, individuals with severe renal impairment, or patients with heart failure. The use of this medication should be discontinued before and after tests using iodinated contrast agents, and it may be resumed only after renal function has been confirmed to be normal. If the patient undergoes major surgery or experiences a severe infection, the use of this medication should also be temporarily halted, and it should be restarted only after the patient resumes normal food intake and renal function is restored. Since this medication may be affected by renal function, regular monitoring of renal function is essential before and during treatment. Patients with heart failure or a history of pancreatitis should take special care when using this medication and should discontinue it immediately and consult a physician if symptoms of pancreatitis appear. This medication may cause hypoglycemia; therefore, when taken with insulin or sulfonylureas, patients should be alert for symptoms of hypoglycemia and dosage adjustments may be necessary. There is an increased risk of urinary tract infections and genital fungal infections; therefore, prompt treatment should be sought if symptoms of infection occur. During treatment, dehydration, hypotension, and fluid loss may occur, so particularly in the elderly or individuals with cardiovascular disease, careful monitoring of blood pressure and fluid status is essential. This medication should not be administered to patients with impaired liver function, and consultation with a physician should occur immediately if symptoms of liver dysfunction appear. There is a risk of vitamin B12 deficiency; hence, patients on long-term therapy should regularly check their vitamin B12 levels. Alcohol consumption should be avoided while taking this medication, as excessive alcohol intake can increase the risk of lactic acidosis. Caution is required when driving or operating machinery due to the possibility of hypoglycemia, particularly when taken with insulin or sulfonylureas. Tablets should be swallowed whole without chewing or crushing, and it is normal for the tablet coating to be excreted in the stool. This medication may interact with other drugs; therefore, any other medications being taken must be disclosed to a doctor or pharmacist.

Side effects

  • Lactic acidosis
  • death cases
  • allergic reactions
  • urinary tract infection
  • pyelonephritis
  • urosepsis
  • vaginomycosis
  • vulvitis
  • balanitis
  • genital infections
Show 206 more
  • perineal necrosis
  • allergic reactions
  • angioedema
  • urticaria
  • hypoglycemia
  • thirst
  • ketoacidosis
  • cough
  • constipation
  • pancreatitis
  • oral ulcer
  • itching
  • rash
  • vesiculobullous pemphigoid
  • rhabdomyolysis
  • decreased fluid volume
  • increased urination
  • dysuria
  • interstitial nephritis
  • increased amylase
  • increased lipase
  • increased hematocrit
  • increased serum lipids
  • vitamin B12 deficiency
  • taste disturbance
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
  • urticaria
  • rash
  • constipation
  • epigastric pain
  • enterocolitis
  • bowel obstruction
  • gastritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer's type dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • colorectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage kidney disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • diarrhea
  • vomiting
  • gastritis
  • irritable bowel syndrome
  • abdominal pain
  • oral burning syndrome
  • colitis
  • abdominal discomfort
  • dysphagia
  • gastric ulcer
  • gum bleeding
  • tooth loss
  • hemorrhoids
  • lower abdominal pain
  • soft tissue infection
  • pharyngitis
  • scrub typhus
  • periodontitis
  • tonsillitis
  • laryngitis
  • chronic otitis media
  • perionychium infection
  • peritonsillar abscess
  • pulmonary tuberculosis
  • subcutaneous abscess
  • complete white ringworm
  • dental abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • nasopharyngitis
  • upper respiratory tract infection
  • periodontitis
  • dental abscess
  • positional dizziness
  • sensory loss
  • paresthesia
  • amnesia
  • carotid artery stenosis
  • facial paralysis
  • memory impairment
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • drowsiness
  • CNS-origin vertigo
  • peripheral edema
  • facial edema
  • peripheral swelling
  • chills
  • strange feelings
  • edema
  • pain at puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • chest pain
  • chest discomfort
  • weakness
  • itching
  • insomnia
  • depression
  • hypertension
  • benign prostatic hyperplasia
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • obesity
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • ocular discomfort
  • conjunctival injection
  • pathologic myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • rhegmatogenous retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual phlegm
  • epistaxis
  • otalgia
  • positional vertigo
  • otalgia
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • nausea
  • dyspepsia
  • headache
  • chest discomfort
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • scrotal pain
  • sexual dysfunction
  • vaginal discharge

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. The recommended storage temperature is room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Yellow oval film-coated sustained release tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.